Search

Introduction: Stroke is the third most common cause of death in the world. The risk of emerging factors for stroke is plasma homocysteine. Subjects & Methods: A descriptive-analytic study was performed on patients with ischemic stroke referring to Tabriz hospitals. We entered the patients' information, including demographic information of patients, hypertension and etc along with laboratory results of homocysteine assay for patients' blood samples into SPSS v16 statistical analysis program. Results: A total of 100 patients with ischemic stroke were evaluated who their average age was 65.83±15.32 years and also 54.54% were men and 46% were women, 45% were with one risk factor, 50% had hypertension, 13% diabetes, 18% hyperlipidemia, 14% a recent MI history and 31% had smoking history. Overall 74% of patients were with no stroke history, homosystein level in studied patients was 20.40±12.24 mmol/lit and 49% had normal level of homosystein. Homosystein level was evaluated with gender (p=0.876), age (p=0.004) and NIHSS (p=0.745) and also NIHSS level with gender (p=0.058), age (p=0.876), HTN (p=0.070), HLP (p=0.103), DM (p=0.999), and history of MI (p=0.262) and history of CVA (p=0.964), NIHSS level with smoking (p=0.109) and homosystein level (p=0.013). Data analysis showed that the level of homocysteine with hypertension (P=0.021) has a significant relationship. Conclusion: The results of this study showed that increased homocysteine has a high prevalence in patients with stroke. [ABSTRACT FROM AUTHOR]

Background: Breast cancer is both the prevailing malignancy and the most common cause of cancer death among women. Many factors may play a role in the susceptibility to the breast cancer and Oxygen Free Radicals may be one of these. There are various known antioxidant systems against oxidative stress, including ParaoxonaseI. The aim of this study was to investigate the association between rs854560 polymorphism in the PON1 gene in patients with breast cancer. Materials and Methods: We performed genotyping analysis using polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) assay in a case–control study of 83 confirmed breast cancer patients and 100 cancer-free controls in Markazi Province. Results: In our study of the PON1 gene L55M polymorphism, the LL genotype was found in 2 (2.40%) patients, whereas the LM genotype was found in 69 (83.13%) patients. The MM genotype was present in 12 (14.45%) patients. In the control group, LL, LM and MM genotypes were found in 4 (4%), 81 (81%), and 15 (15%) subjects, respectively. There was no statistically significant difference between patient and control groups in terms of the PON1 gene L55M polymorphism (p= 0.825). Allele distributions were different but this difference did not reach statistical significance (p= 0.920). Conclusion: We found no association between M55L polymorphism and breast cancer. [ABSTRACT FROM AUTHOR]

Background: Paraoxonase 1 activity shows a decline in patients with coronary artery disease. The C to T change in the -107 position of promoter is the most important genetic determinant of serum levels of paraoxonase 1. Study of this polymorphism and its relationship with the type of fatty acid composition of phospholipids in HDL particles can be found in the common pursuit of better medicines and considered in drug treatment Materials and Methods: In this descriptive study, 265 patients were selected and divided into two groups based on LDL level (131 in case and 134 in control groups). Lipid profile and paraoxanase 1 activity were measured by commercial kits and spectrophotometry method, respectively. Molecular studies were performed by PCR-RFLP after DNA extraction. Fatty acids of HDL phospholipids were measured by gas chromatography technic. Results: PON1aryl esterase activity had no significant changes after treatment with lovastatin but paraoxonase activity had more significant increases in the CC genitype of -C/T107 polymorphism. Oleic acid, linoleic acid, and icosapentanioc acid percents in HDL phospholipids were increased by lovastatin. Conclusion: Treatment with lovastatin in the CC genotype has probably a more protective effect against cardiovascular diseases. Following treatment, in patients with higher paraoxanase 1 activity, oleic acid and linoleic acid increased in HDL phospholipids. [ABSTRACT FROM AUTHOR]